Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-1513
- Development stage
- Preclinical
- Lead developer
- Ahead Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
AT-1513 is an investigational nanoparticle-based therapy developed by Ahead Therapeutics for the treatment of Neuromyelitis Optica (NMO). The drug utilizes a proprietary platform for in vivo immune reprogramming, employing tolerogenic nanoparticles to induce antigen-specific immune tolerance. By mimicking the natural process of apoptotic cell clearance, these nanoparticles aim to restore immune balance and prevent the autoimmune attack on the central nervous system characteristic of NMO, without the need for broad systemic immunosuppression.
Beyond the preview
Go deeper on AT-1513.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-1513.